Inhaltsverzeichnis
Auswahl der wissenschaftlichen Literatur zum Thema „Anti-SRP“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Anti-SRP" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Anti-SRP"
Suzuki, Shigeaki. „Anti-SRP myopathy“. Rinsho Shinkeigaku 51, Nr. 11 (2011): 961–63. http://dx.doi.org/10.5692/clinicalneurol.51.961.
Der volle Inhalt der QuelleDandasena, Tarini, Vaibhav Ingle, Abhishek Singhai und Saurabh Saigal. „Anti-SRP-positive necrotising myopathy concurrent with breast malignancy“. BMJ Case Reports 16, Nr. 12 (Dezember 2023): e254702. http://dx.doi.org/10.1136/bcr-2023-254702.
Der volle Inhalt der QuelleAllenbach, Yves, Louiza Arouche-Delaperche, Corinna Preusse, Helena Radbruch, Gillian Butler-Browne, Nicolas Champtiaux, Kuberaka Mariampillai et al. „Necrosis in anti-SRP+ and anti-HMGCR+myopathies“. Neurology 90, Nr. 6 (12.01.2018): e507-e517. http://dx.doi.org/10.1212/wnl.0000000000004923.
Der volle Inhalt der QuelleSuzuki, Shigeaki. „Anti-SRP myopathy: different entity from myositis“. Rinsho Shinkeigaku 52, Nr. 11 (2012): 1148–50. http://dx.doi.org/10.5692/clinicalneurol.52.1148.
Der volle Inhalt der QuelleZhuo, De-Bing, und Hui Cao. „Fast Sound Source Localization Based on SRP-PHAT Using Density Peaks Clustering“. Applied Sciences 11, Nr. 1 (05.01.2021): 445. http://dx.doi.org/10.3390/app11010445.
Der volle Inhalt der QuelleMartínez-Rodríguez, Pablo, María Escribano-Iglesias, Ángel-P. Crisolino-Pozas, Noelia Cubino-Boveda, Miriam López-Parra, Miguel Marcos und Antonio-J. Chamorro. „Plasma Exchange in Anti-Signal Recognition Particle Myopathy: A Systematic Review and Combined Analysis of Patient Individual Data“. Journal of Personalized Medicine 14, Nr. 5 (27.04.2024): 461. http://dx.doi.org/10.3390/jpm14050461.
Der volle Inhalt der QuelleShinde, Ujwala A., und Shivkumar S. Kanojiya. „Serratiopeptidase Niosomal Gel with Potential in Topical Delivery“. Journal of Pharmaceutics 2014 (20.03.2014): 1–9. http://dx.doi.org/10.1155/2014/382959.
Der volle Inhalt der QuelleBergua, Cécile, Hélène Chiavelli, Yves Allenbach, Louiza Arouche-Delaperche, Christophe Arnoult, Gwladys Bourdenet, Laetitia Jean et al. „In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy“. Annals of the Rheumatic Diseases 78, Nr. 1 (11.10.2018): 131–39. http://dx.doi.org/10.1136/annrheumdis-2018-213518.
Der volle Inhalt der QuelleEura, N., T. Shiota, M. Ozaki, N. Iguchi, Y. Uchihara, H. Nanaura, K. Fukushima et al. „P.11Clinicopathological difference between anti-SRP and anti-HMGCR myopathy“. Neuromuscular Disorders 29 (Oktober 2019): S44. http://dx.doi.org/10.1016/j.nmd.2019.06.040.
Der volle Inhalt der QuelleBotos, Balázs, Melinda Nagy-Vincze und Katalin Dankó. „Anti-SRP-pozitív myositises betegeink klinikai sajátosságai és terápiára adott válaszuk“. Orvosi Hetilap 158, Nr. 35 (September 2017): 1382–89. http://dx.doi.org/10.1556/650.2017.30827.
Der volle Inhalt der QuelleDissertationen zum Thema "Anti-SRP"
Arouche-Delaperche, Louiza. „Effet des auto-anticorps anti-SRP et anti-HMGCR sur le muscle strié squelettique“. Thesis, Paris 6, 2016. http://www.theses.fr/2016PA066389/document.
Der volle Inhalt der QuelleImmune mediated necrotizing myopathy (IMNM) is recognized as a separate entity among inflammatory myopathies. IMNM is a severe disabling muscle disease requiring prolonged combination of corticosteroid and immunosuppressive drugs. IMNM is morphologically defined by predominant muscle fiber necrosis and no or little inflammation, and is associated with important variation of the size of the fiber. However pathogenic mechanisms involved in muscle necrosis and muscle atrophy are largely unknown. IMNM may be associated with either anti-SRP or anti-HMGCR auto-antibodies (aAbs). The titer of these aAbs, targeting ubiquitous cytoplasmic proteins, is correlated with the disease activity suggesting their pathogenic role. In this thesis, we described the morphology of skeletal muscle alterations occurring in both conditions of anti-SRP+ or anti-HMGCR+ patients, studied the role of the Abs in (i) the necrosis mechanisms and the associated inflammation; (ii) by analyzing the atrophy and the regeneration mechanisms. Muscle histological analysis of anti-SRP+ and anti-HMGCR+ patients showed a random distribution of necrotic fibers that was more pronounced in anti-SRP+ patients. Creatine Phosphokinase levels; myolysis indicator, and muscle regeneration were correlated with the proportion of necrotic fibers. Inflammation was regularly observed in IMNM muscle patients. Macrophages were the most abundant but T cells densities were in a quarter of cases in the same range as myositis controls. CD68+iNOS+ macrophages and a Th-1 immune environment were also observed and involved in ongoing myophagocytosis. Of note, macrophages with alternative activation were also detected. Humoral immunity with activation of the classical pathway of the complement cascade was observed in IMNM. Positive membrane staining for SRP and HMGCR proteins, on some muscle fibers, was detected both in vitro and in muscle biopsies of IMNM patients. An important proportion of small fibers corresponding to both atrophic and regenerating fibers was observed in anti-SRP+ and anti-HMGCR+ patients. In vitro, anti-SRP and anti-HMGCR aAbs induced muscle fibers atrophy and increased the transcription of MAFbx and Trim63. In addition, the muscle fiber atrophy was associated with high level of inflammatory cytokines such TNF, IL-6 and ROS. Muscle regeneration in vitro was also affected by impairing the myoblasts fusion in presence of anti-SRP and anti-HMGCR Abs. This default was associated with a decrease production of anti-inflammatory cytokines: IL-4 and IL-13. Of note, the addition of IL-4 and/or IL-13 totally rescued the fusion. Together those data suggest that these aAbs have a pathogenic effect on muscle. Anti-SRP and anti-HMGCR are involved in muscle atrophy and affect the regeneration. The role of these aAbs in muscle damages occurring in IMNM was highlighted and emphasizes the potential interest of targeted therapies
Arouche-Delaperche, Louiza. „Effet des auto-anticorps anti-SRP et anti-HMGCR sur le muscle strié squelettique“. Electronic Thesis or Diss., Paris 6, 2016. https://accesdistant.sorbonne-universite.fr/login?url=https://theses-intra.sorbonne-universite.fr/2016PA066389.pdf.
Der volle Inhalt der QuelleImmune mediated necrotizing myopathy (IMNM) is recognized as a separate entity among inflammatory myopathies. IMNM is a severe disabling muscle disease requiring prolonged combination of corticosteroid and immunosuppressive drugs. IMNM is morphologically defined by predominant muscle fiber necrosis and no or little inflammation, and is associated with important variation of the size of the fiber. However pathogenic mechanisms involved in muscle necrosis and muscle atrophy are largely unknown. IMNM may be associated with either anti-SRP or anti-HMGCR auto-antibodies (aAbs). The titer of these aAbs, targeting ubiquitous cytoplasmic proteins, is correlated with the disease activity suggesting their pathogenic role. In this thesis, we described the morphology of skeletal muscle alterations occurring in both conditions of anti-SRP+ or anti-HMGCR+ patients, studied the role of the Abs in (i) the necrosis mechanisms and the associated inflammation; (ii) by analyzing the atrophy and the regeneration mechanisms. Muscle histological analysis of anti-SRP+ and anti-HMGCR+ patients showed a random distribution of necrotic fibers that was more pronounced in anti-SRP+ patients. Creatine Phosphokinase levels; myolysis indicator, and muscle regeneration were correlated with the proportion of necrotic fibers. Inflammation was regularly observed in IMNM muscle patients. Macrophages were the most abundant but T cells densities were in a quarter of cases in the same range as myositis controls. CD68+iNOS+ macrophages and a Th-1 immune environment were also observed and involved in ongoing myophagocytosis. Of note, macrophages with alternative activation were also detected. Humoral immunity with activation of the classical pathway of the complement cascade was observed in IMNM. Positive membrane staining for SRP and HMGCR proteins, on some muscle fibers, was detected both in vitro and in muscle biopsies of IMNM patients. An important proportion of small fibers corresponding to both atrophic and regenerating fibers was observed in anti-SRP+ and anti-HMGCR+ patients. In vitro, anti-SRP and anti-HMGCR aAbs induced muscle fibers atrophy and increased the transcription of MAFbx and Trim63. In addition, the muscle fiber atrophy was associated with high level of inflammatory cytokines such TNF, IL-6 and ROS. Muscle regeneration in vitro was also affected by impairing the myoblasts fusion in presence of anti-SRP and anti-HMGCR Abs. This default was associated with a decrease production of anti-inflammatory cytokines: IL-4 and IL-13. Of note, the addition of IL-4 and/or IL-13 totally rescued the fusion. Together those data suggest that these aAbs have a pathogenic effect on muscle. Anti-SRP and anti-HMGCR are involved in muscle atrophy and affect the regeneration. The role of these aAbs in muscle damages occurring in IMNM was highlighted and emphasizes the potential interest of targeted therapies
Bergua, Cecile. „Pathogénicité des auto-anticorps anti-SRP et anti-HMGCR au cours des myopathies nécrosantes auto-immunes“. Thesis, Normandie, 2017. http://www.theses.fr/2017NORMR067/document.
Der volle Inhalt der QuelleAutoimmune myopathies (AIM), classically called myositis or idiopathic inflammatory myopathies, represent a group of diseases characterized by clinical, histopathologic and biologic properties. One of the most notable properties is the presence of autoantibodies (aAb) in approximately 60% of patients. AIM includes five principal entities: dermatomyositis, polymyositis, inclusion body myositis, overlap myositis including the anti-synthetase syndrome and immune-mediated necrotizing myopathies (IMNM). IMNM have recently been individualized among AIM as severe diseases frequently associated with aAb directed against Signal Recognition Particle (SRP) or 3-Hydroxy-3-MethylGlutaryl-CoA Reductase (HMGCR). Since SRP and HMGCR have an intracellular localization, the role of anti-SRP and anti-HMGCR aAb in the pathophysiology of IMNM remains unclear. Anti-SRP and anti-HMGCR aAb were recently shown to be pathogenic to muscle cells in vitro but in vivo effects remain unknown.During this thesis, I studied the pathophysiological role of anti-SRP and anti-HMGCR aAb in vivo in mice. Passive transfer of IgG purified from plasma of IMNM patients positive for anti-SRP and anti-HMGCR aAb to wild-type mice elicited a muscle weakness. Immune-deficient Rag2-/- mice presented a prolonged muscle deficit, whereas complement component C3 deficient mice had limited signs. Mice injected with anti-SRP+ IgG displayed a strong muscle weakness with mild myocytic necrosis. The muscle deficit was milder and histopathologic findings were not always present in mice receiving anti-HMGCR+ IgG. This is in accordance with clinical findings in anti-SRP+ patients which present a more severe disease than anti-HMGCR+ patients. When supplemented with human complement, mice receiving anti-HMGCR+ IgG showed a more severe muscle deficit. This supplementation increased the deficit induced by anti-SRP IgG in a milder way. In collaboration with INSERM UMRS974, we showed that the targets SRP and HMGCR can be detected on the surface of myofibres in vitro, suggesting that they could be accessible to aAb in vivo.Together, these results demonstrate for the first time the pathogenic role of anti-SRP and anti-HMGCR aAb in vivo and the implication of complement, contributing to a progress in the comprehension of MNAI pathophysiology
Bendavid-Anquetil, Céline. „Rôle des anticorps monoclonaux au cours des myopathies auto-immunes : de l’étude des auto-anticorps spécifiques des myopathies nécrosantes auto-immunes à la description physiopathologique des myosites induites par l’immunothérapie anti-tumorale“. Electronic Thesis or Diss., Sorbonne université, 2021. http://www.theses.fr/2021SORUS257.
Der volle Inhalt der QuelleMyositis is a rare autoimmune disease that may occur spontaneously, idiopathic inflammatory myopathies, or be induced by treatments such as immune checkpoint inhibitors (ICI). Among myositis, this work focused on the study of two entities: immune-mediated necrotizing myopathy (IMNM), and ICI-induced myositis. Inflammatory myopathies are separated into homogeneous subgroups in terms of clinical, biological, and histological phenotype thanks to the identification of myositis-specific autoantibodies. Each of these entities is associated with antibodies that play a role in the occurrence of the disease by different mechanisms. In IMNM, anti-SRP (signal recognition particle) autoantibodies appear to play a direct pathogenic role via activation of the classical complement pathway. Thirteen anti-SRP autoantibodies from patient samples were produced, including five autoantibodies specifically recognizing SRP by two different techniques. These human anti-SRP autoantibodies will be used to develop models of IMNM and to understand their mechanisms of action as well as to define their antigenic targets. Regarding ICI-induced myositis, therapeutic monoclonal antibodies directed against inhibitory co-stimulatory molecules induce a break of immune tolerance within the muscle tissue. The description of a series of patients from pharmacovigilance database allowed us to characterize a specific clinical phenotype associated with a poor prognosis, particularly in the case of associated myocarditis. The study of the systemic immune response and of the muscle transcriptomic profile has highlighted a central role of cytotoxic T lymphocytes and macrophages in the pathophysiology of the disease.Eventually, the description of pathophysiological mechanisms is mandatory to identify new therapeutic targets and then improve myositis treatment strategy
Trönnberg, Frida. „State Regulation of Anti-Democratic Parties : A Comparative Study of Germany, Spain and Sweden“. Thesis, Linköpings universitet, Statsvetenskap, 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-98267.
Der volle Inhalt der QuelleBuchteile zum Thema "Anti-SRP"
„Anti-SRP antibodies“. In Dictionary of Rheumatology, 16. Vienna: Springer Vienna, 2009. http://dx.doi.org/10.1007/978-3-211-79280-3_68.
Der volle Inhalt der QuelleKonferenzberichte zum Thema "Anti-SRP"
Mazzuco Dallabrida, Giulia, Guilherme Sanzhez Corrêa, Nathália de Assunção und Ivânio Alves Pereira. „IMMUNO-MEDIATED NECROTIZING MYOPATHY ASSOCIATED WITH POSITIVE ANTI-SRP ANTIBODY“. In Congresso Brasileiro de Reumatologia 2020. Sociedade Brasileira de Reumatologia, 2021. http://dx.doi.org/10.47660/cbr.2020.17477.
Der volle Inhalt der QuelleFigueiredo, Letícia Queiroga de, Joaquim Ivo Vasques Dantas Landim, Fernanda Oliveira de Andrade Lopes, Rodrigo de Moura Rodrigues, Andreia Coimbra Sousa, Rosa Maria Rodrigue Pereira, Henrique Ayres Mayrink Giardini, Lissiane Karine Noronha Guedes, Adriana Coracini Tonacio und Isabele Parente de Brito Antonelli. „Immune-mediated necrotizing myopathy with anti-SRP and exposition to statin“. In XXXIX Congresso Brasileiro de Reumatologia. Sociedade Brasileiro de Reumatologia, 2022. http://dx.doi.org/10.47660/cbr.2022.1898.
Der volle Inhalt der QuelleWerner, R., R. M. Marron und J. I. Stewart. „An Atypical Presentation of Fulminant Respiratory Failure Due to Anti-SRP Antibody Myositis“. In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6639.
Der volle Inhalt der Quelle